Daymark Wealth Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$30.6M Buy
25,552
+11,076
+77% +$11.3M 0.75% 34
2026
Q1
$13.3M Buy
14,476
+1,112
+8% +$1.13M 0.42% 48
2025
Q4
$14.4M Sell
13,364
-19
-0.1% -$18.2K 0.46% 47
2025
Q3
$10.2M Buy
13,383
+2,119
+19% +$1.58M 0.35% 59
2025
Q2
$8.78M Buy
11,264
+473
+4% +$368K 0.33% 61
2025
Q1
$8.91M Buy
10,791
+57
+0.5% +$47.4K 0.38% 56
2024
Q4
$8.29M Sell
10,734
-986
-8% -$816K 0.35% 61
2024
Q3
$10.4M Buy
11,720
+162
+1% +$146K 0.44% 51
2024
Q2
$10.5M Buy
11,558
+917
+9% +$734K 0.48% 45
2024
Q1
$8.28M Sell
10,641
-14
-0.1% -$9.96K 0.45% 53
2023
Q4
$6.21M Buy
10,655
+173
+2% +$101K 0.38% 60
2023
Q3
$5.63M Buy
10,482
+583
+6% +$300K 0.39% 58
2023
Q2
$4.64M Buy
9,899
+3,965
+67% +$1.66M 0.34% 71
2023
Q1
$2.04M Buy
5,934
+65
+1% +$21.9K 0.27% 80
2022
Q4
$2.15M Buy
+5,869
New +$2.08M 0.38% 59

Other funds holding LLY

Daymark Wealth Partners's LLY Position: Q2 2026 in Review

Daymark Wealth Partners increased its Eli Lilly (LLY) stake by 77% in Q2 2026, buying an estimated $11.3M and bringing the position to 25,552 shares worth $30.6M. The position accounts for 0.75% of the portfolio, ranked #34.

Daymark Wealth Partners first reported a position in LLY in Q4 2022 and has held it in 15 quarters since. 4,635 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Daymark Wealth Partners held 25,552 shares of Eli Lilly worth $30.6M as of Q2 2026.
  • Daymark Wealth Partners bought 11,076 Eli Lilly shares in Q2 2026, an estimated $11.3M.
  • Eli Lilly made up 0.75% of Daymark Wealth Partners's portfolio in Q2 2026, its #34 holding.
  • Daymark Wealth Partners first reported a position in Eli Lilly in Q4 2022 and has held it in 15 quarters since.
  • 4,635 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.